GlassScriptPhysician profile
Theodore Conrad Tan
NPI 1003046624
$5,979.26
in general payments reported to CMS, 2019-2025
45 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $1,103 · 2021: $1,100 · 2022: $813 · 2023: $577 · 2024: $503 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.04 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $906.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $598.24 | 2019-2025 | Breztri, Airsupra, Flumist Quadrivalent |
| Amgen INC. | $590.74 | 2019-2025 | Prolia, Evenity, Repatha |
| Pfizer INC. | $544.61 | 2019-2025 | |
| Lilly USA, LLC | $435.98 | 2019-2025 | Jardiance, Mounjaro |
| Astellas Pharma US INC | $318.43 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $272.30 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $251.45 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.69 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $163.33 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $153.54 | 2021-2025 | Freestyle Libre 3, Assurity |
| Sanofi-Aventis U.S. LLC | $143.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $143.32 | 2019-2023 | |
| Amarin Pharma, INC. | $132.50 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $129.69 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Conrad Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.